A case for synchronous reduction of testicular androgen, adrenal androgen and prolactin for the treatment of advanced carcinoma of the prostate
- 30 June 1995
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 31 (6) , 871-875
- https://doi.org/10.1016/0959-8049(95)00233-2
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Orchiectomy and Nilutamide or Placebo as Treatment of Metastatic Prostatic Cancer in a Multinational Double-Blind Randomized TrialJournal of Urology, 1993
- A Multicenter Randomized Trial Comparing the Luteinizing Hormone-Releasing Hormone Analogue Goserelin Acetate Alone and with Flutamide in the Treatment of Advanced Prostate CancerJournal of Urology, 1991
- Pituitary Adrenal and Gonadal Endocrine Suppression for the Primary Treatment of Prostate CancerBritish Journal of Urology, 1990
- Zoladex plus Flutamide vs. Orchidectomy for Advanced Prostatic CancerEuropean Urology, 1990
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patientsBritish Journal of Cancer, 1988
- Treatment of Advanced Prostatic CancerUrologic Clinics of North America, 1987
- Androgen Suppression by Hydrocortisone without Aminoglutethimide in Orchiectomised Men with Prostatic CancerBritish Journal of Urology, 1987
- New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgensThe Prostate, 1983
- STUDIES ON PROSTATIC CANCERArchives of Surgery, 1941